000 01888cam  2200313zi 4500
0019.871535
003CaOODSP
00520221107163421
006m     o  d f      
007cr |||||||||||
008190412e20190402onc    #o    f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aYN5-176/2019E-PDF
24504|aThe impact of the Canada-United States-Mexico Agreement on prescription drug expenditures in Canada.
264 1|aOttawa, Canada : |bOffice of the Parliamentary Budget Officer = Bureau du directeur parlementaire du budget, |c2 April 2019.
300 |a1 online resource (37 pages).
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Incidence de l'Accord Canada-États-Unis-Mexique sur les dépenses en médicaments d'ordonnance au Canada.
500 |aCover title.
504 |aIncludes bibliographical references.
520 |a"The Canada-United States-Mexico Agreement (CUSMA) provides an extension to the term of protection for data resulting from drug trials. The extension applies to a category of pharmaceuticals known as innovative biologics. These are drugs with complex structures that have become increasingly popular. In recent years, pharmaceutical companies have been seeking extensions to the terms of data protection for such biologics to bolster the market exclusivity given by patents"--Executive summary, page 1.
69207|2gccst|aTrade agreements
69207|2gccst|aDrugs
7101 |aCanada. |bOffice of the Parliamentary Budget Officer.
77508|tIncidence de l'Accord Canada-États-Unis-Mexique sur les dépenses en médicaments d'ordonnance au Canada.|w(CaOODSP)9.871626
85640|qPDF|s870 KB|uhttps://publications.gc.ca/collections/collection_2019/dpb-pbo/YN5-176-2019-eng.pdf